Health risks of lipodystrophy and abdominal fat accumulation: Therapeutic possibilities with leptin and human growth hormone

Growth Hormone and IGF Research

Volumn 13, Issue SUPPL. A, 2003, Pages

  Van Gaal, Luc F ^a   Mertens, Ilse L ^a   Abrams, Pascale J ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Acquired lipodystrophy (LD); Adiponectin; Animal and human congenital lipoatrophy; Insulin resistance; Leptin; Recombinant human growth hormone (rhGH); Visceral fat

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ADIPONECTIN; ANTIDIABETIC AGENT; ANTIRETROVIRUS AGENT; HUMAN GROWTH HORMONE; LEPTIN; METFORMIN; PROTEINASE INHIBITOR; RESISTIN; SOMATOMEDIN; THIAZOLIDINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTOSOMAL DISORDER; BODY FAT; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HEALTH HAZARD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPID STORAGE; LIPODYSTROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL;

EID: 0141855019     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-6374(03)00046-7     Document Type: Article

References (46)

1. P.T. James, R. Leach, E. Kalamara, M. Shayeghi, The worldwide obesity epidemic, Obes. Res. 9 (2001) 228S-233S.
2. B. Larsson, K. Svardsudd, L. Welin, L. Wilhelmsen, P. Bjorntorp, G. Tibblin, Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913, Br. Med. J. 288 (1984) 1401-1404.
3. L.O. Ohlson, B. Larsson, K. Svardsudd, L. Welin, H. Eriksson, L. Wilhelmsen, P. Bjorntorp, G. Tibblin, The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913, Diabetes 34 (1985) 1055-1058.
4. S. Lemieux, D. Prud'homme, S. Moorjani, A. Tremblay, C. Bouchard, P.J. Lupien, J.-P. Després, Do elevated levels of abdominal visceral adipose tissue contribute to age-related differences in plasma lipoprotein concentrations in men?, Atherosclerosis 118 (1995) 155-164.
5. J.-P. Després, A. Nadeau, A. Tremblay, M. Ferland, S. Moorjani, P.J. Lupien, G. Theriault, S. Pinault, C. Bouchard, Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women, Diabetes 38 (1989) 304-309.
6. L. Lapidus, C. Bengtsson, B. Larsson, K. Pennart, E. Rybo, L. Sjostrom, Distribution of adipose tissue and risk of cardiovascular disease and death, Br. Med. J. 289 (1984) 1257-1261.
7. D.V. Shapira, R.A. Clark, P.A. Wolff, A.R. Jarrett, N.B. Kumar, N.M. Aziz, Visceral obesity and breast cancer risk, Cancer 74 (1994) 632-639.
8. K.M. Rexrode, V.J. Carey, C.H. Hennekens, E.E. Walters, G.A. Colditz, M.J. Stampfer, W.C. Willett, J.E. Manson, Abdominal adiposity and coronary heart disease in women, JAMA 280 (1998) 1843-1848.
9. J.-P. Després, I. Lemieux, D. Prud'homme, Treatment of obesity: need to focus on high risk abdominally obese patients, Br. Med. J. 322 (2001) 716-720.
10. I. Lemieux, A. Pascot, D. Prud'homme, N. Alméras, P. Bogaty, A. Nadeau, J. Bergeron, J.-P. Després, Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity, Arterioscler. Thromb. Vasc. Biol. 21 (2001) 961-967.
11. I. Mertens, L.F. Van Gaal, Obesity, haemostasis and the fibrinolytic system, Obes. Rev. 3 (2002) 85-101.
12. C. Weyer, T. Funahashi, S. Tanaka, K. Hotta, Y. Matsuzawa, R.E. Pratley, P.A. Tataranni, Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia, J. Clin. Endocrinol. Metab. 86 (2001) 1930-1935.
13. L. Van Gaal, M. Wauters, I. De Leeuw, The beneficial effects of modest weight loss on cardiovascular risk factors, Int. J. Obes. 21 (1997) S5-S9.
14. J. Moitra, M.M. Mason, M. Olive, D. Krylov, O. Gavrilova, B. Marcus-Samuels, L. Feigenbaum, E. Lee, T. Aoyama, M. Eckhaus, M.L. Reitman, C. Vinson, Life without white fat: a transgenic mouse, Genes Dev. 12 (1998) 3168-3181.
15. K. Johansen, M.H. Rasmussen, L.L. Kjems, A. Astrup, An unusual type of familial lipodystrophy, J. Clin. Endocrinol. Metab. 80 (1995) 3442-3446.
16. O. Gavrilova, B. Marcus-Samuels, D. Graham, J.K. Kim, G.I. Shulman, A.L. Castle, C. Vinson, M. Eckhaus, M.L. Reitman, Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice, J. Clin. Invest. 105 (2000) 271-278.
17. W. Berardinelli, An undiagnosed endocrinometabolic syndrome: report of two cases, J. Clin. Endocrinol. Metab. 14 (1954) 193-204.
18. S.N.J. Jackson, T.A. Howlett, P.G. McNally, S. O'Rahilly, R.C. Trembath, Dunnigan syndrome: an autosomal dominant form of partial lipodystrophy, QJM 90 (1997) 27-36.
19. L. Van Maldergem, J. Magré, T.E. Khallouf, T. Gedde-Dahl Jr., M. Delepine, O. Trygstad, E. Seemanova, T. Stephenson, C.S. Albott, F. Bonnici, V.R. Panz, J.L. Medina, P. Bogalho, F. Huet, S. Savasta, A. Verloes, J.J. Robert, H. Loret, M. De Kerdanet, N. Tubiana-Rufi, A. Megarbane, J. Maassen, M. Polak, D. Lacombe, C.R. Kahn, E.L. Silveira, F.H. D'Abronzo, F. Grigorescu, M. Lathrop, J. Capeau, S. O'Rahilly, Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy, J. Med. Genet. 39 (2002) 722-733.
20. J.A. Janssen, N. Hoogerbrugge, J.W. van Neck, P. Uitterlinden, S.W.J. Lamberts, The IGF-I/IGFBP system in congenital partial lipodystrophy, Clin. Endocrinol. 49 (1998) 465-473.
21. A. Gard, M. Vinaitheerthan, P.T. Weatherall, A.M. Bowcock, Phenotypic heterogeneity in patients with familial partial lipodystrophy (Dunnigan variety) related to the site of missense mutations in Lamin A/C gene, J. Clin. Endocrinol. Metab. 86 (2001) 59-65.
22. C.J. Lelliot, L. Logie, C.P. Sewter, D. Berger, P. Jani, F. Blows, S. O'Rahilly, A. Vidal-Puig, Lamin expression in human adipose cells in relation to anatomical site and differentiation state, J. Clin. Endocrinol. Metab. 87 (2002) 728-734.
23. A. Carr, K. Samaras, A. Thorisdottir, G.R. Kaufmann, D.J. Chisholm, D.A. Cooper, Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study, Lancet 353 (1999) 2093-2099.
24. S.R. Penzak, S.K. Chuck, Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment, Scand. J. Infect. Dis. 32 (2000) 111-113.
25. E. Florence, C. Dreezen, R. Considine, M. Wauters, L. Van Gaal, R. Colebunders, Changes in plasma leptin levels as a potential predictor for the development of lipodystrophy among HIV positive adults, submitted for publication.
26. K. Koppel, G. Bratt, S. Schulman, H. Bylund, E. Sandstrom, Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy, JAIDS 29 (2002) 441-449.
27. E. Renard, J. Fabre, F. Paris, J. Reynes, J. Bringer, Syndrome of body fat redistribution in HIV-1 infected patients: relationships to cortisol and catecholamines, Clin. Endocrinol. 51 (1999) 223-230.
28. L.F. Van Gaal, M.A. Wauters, I.L. Mertens, R.V. Considine, I.H. De Leeuw, Clinical endocrinology of human leptin, Int. J. Obes. 23 (1999) S29-S36.
29. I.S. Farooqi, S.A. Jebb, G. Langmack, E. Lawrence, C.H. Cheetham, A.M. Prentice, I.A. Hughes, M.A. McCamish, S. O'Rahilly, Effects of recombinant leptin therapy in a child with congenital leptin deficiency, N. Engl. J. Med. 341 (1999) 879-884.
30. M. Wauters, R.V. Considine, L.F. Van Gaal, Human leptin: from an adipocyte hormone to an endocrine mediator, Eur. J. Endocrinol. 143 (2000) 293-311.
31. C. Grunfeld, M. Pang, J.K. Shigenaga, P. Jensen, R. Lallone, J. Friedman, K.R. Feingold, Serum leptin levels in the acquired immunodeficiency syndrome, J. Clin. Endocrinol. Metab. 81 (1996) 4342-4346.
32. Y. Arita, S. Kihara, N. Ouchi, M. Takahashi, K. Maeda, J. Miyagawa, K. Hotta, I. Shimomura, T. Nakamura, K. Miyaoka, H. Kuriyama, M. Nishida, S. Yamashita, K. Okubo, K. Matsubara, M. Muraguchi, Y. Ohmoto, T. Funahashi, Y. Matsuzawa, Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity, Biochem. Biophys. Res. Commun. 257 (1999) 79-83.
33. P.W. Mathieson, D.K. Peters, Lipodystrophy in MCGN type II: the clue to links between the adipocyte and the complement system, Nephrol. Dial. Transplant. 12 (1997) 1804-1806.
34. E.A. Oral, V. Simha, E. Ruiz, A. Andewelt, A. Premkumar, P. Snell, A.J. Wagner, A.M. DePaoli, M.L. Reitman, S.I. Taylor, P. Gorden, A. Garg, Leptin replacement therapy for lipodystrophy, N. Engl. J. Med. 346 (2002) 570-578.
35. K.F. Petersen, E.A. Oral, S. Dufour, D. Befroy, C. Ariyan, C. Yu, G.W. Cline, A.M. DePaoli, S.I. Taylor, P. Gorden, G.I. Shulman, Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy, J. Clin. Invest. 109 (2002) 1345-1350.
36. D.B. Savage, S. O'Rahilly, Leptin: a novel therapeutic role in lipodystrophy, J. Clin. Invest. 109 (2002) 1285-1286.
37. C. Colombo, J.J. Cutson, T. Yamauchi, C. Vinson, T. Kadowaki, O. Gavrilova, M.L. Reitman, Transplantation of adipose tissue lacking leptin is unable to reverse the metabolic abnormalities associated with lipoatrophy, Diabetes 51 (2002) 2727-2733.
38. P. Rietschel, C. Hadigan, C. Corcoran, T. Stanley, G. Neubauer, J. Gertner, S. Grinspoon, Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy, J. Clin. Endocrinol. Metab. 86 (2001) 504-510.
39. K. Mulligan, C. Grunfeld, M.K. Hellerstein, R.A. Neese, M. Schambelan, Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection, J. Clin. Endocrinol. Metab. 77 (1993) 956-962.
40. E.S. Engelson, M.J. Glesby, D. Mendez, J.B. Albu, J. Wang, S.B. Heymsfield, D.P. Kotler, Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection, JAIDS 30 (2002) 379-391.
41. S. Mauss, E. Wolf, H. Jaeger, Reversal of protease inhibitor-related visceral abdominal fat accumulation with recombinant human growth hormone, Ann. Int. Med. 131 (1999) 313-314.
42. K. Mulligan, V. Tai, M. Schambelan, Use of growth hormone and other anabolic agents in AIDS wasting, J. Parenter. Enteral Nutr. 23 (1999) S202-S209.
43. C. Hadigan, C. Corcoran, N. Basgoz, Metaformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial, JAMA 284 (2000) 472-477.
44. C. Hadigan, J.B. Meigs, J. Rabe, R.B. D'Agostino, P.W.F. Wilson, I. Lipinska, G.H. Tofler, S. Grinspoon, Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance, J. Clin. Endocrinol. Metab. 86 (2001) 939-943.
45. M.C. Gelato, D.C. Mynarcik, J.L. Quick, R.T. Steigbigel, J. Fuhrer, C.E. Brathwaite, J.S. Brebbia, M.R. Wax, M.A. McNurlan, Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study, JAIDS 31 (2002) 163-170.
46. W.S. Yang, C.Y. Jeng, T.J. Wu, S. Tanaka, T. Funahashi, Y. Matsuzawa, J.P. Wang, C.L. Chen, T.Y. Tai, L.M. Chuang, Synthetic peroxisome proliferator-activated receptor-αc agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients, Diabetes Care 25 (2002) 376-380.